Cohen, Salomon-Yves http://orcid.org/0000-0003-1181-4379
Dominguez, Marcel
Coscas, Florence
Faure, Céline http://orcid.org/0000-0002-7435-7518
Baillif, Stéphanie http://orcid.org/0000-0003-1700-8570
Oubraham, Hassiba http://orcid.org/0000-0002-9004-6867
Kodjikian, Laurent http://orcid.org/0000-0002-3908-6716
Weber, Michel http://orcid.org/0000-0001-5884-1177
,
Funding for this research was provided by:
Bayer
Article History
Received: 20 May 2022
Revised: 28 October 2022
Accepted: 4 November 2022
First Online: 18 November 2022
Declarations
:
: No Independent Ethics Committee or Institutional Review Board approval was obtained because of the study’s observational design in accordance with the requirements of local law and regulations in France. The protocol was reviewed and approved by a French data privacy committee: Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé (CCTIRS) and Commission Nationale de l’Informatique et des Libertés (CNIL). Bayer France received a positive statement from the CCTIRS on June 18, 2014, and an authorization from the CNIL on October 14, 2014, for the RAINBOW study. All patients provided written informed consent for participation in this study.
: Not applicable.
: SYC: consulting fees from Allergan, Bayer, Novartis, Roche, and Théa; CF: consulting fees from Allergan, Bayer, and Novartis; SB: consulting fees from Bayer, Allergan/AbbVie, Horus Pharma, Novartis, and Roche; HO: consulting fees from Allergan, Bayer, Novartis, Roche, and Théa; LK: consulting fees from Allergan/AbbVie, Alcon, Bayer, Krystal Biotech, Novartis, Regeneron, and Théa; MW: member of the French advisory board for Bayer. MD and FC declare no competing interests.